Up Front

• Reflections and Revolutionary Implications of RNAi
  DDT keynoter adn Nobel laureate Craig Mello and his RNAi world.
• Black Swans and Biopharma
  Is pharma ready for the unexpected?
• Cross-Linking Antibodies
  InNexus shares royalties to focus on early development.
• Biomarkers Speeding Cancer Drugs
  THE BIOMARKER REPORT - Companies bet that biomarkers will accelerate drug development.
  By Malorye Allison
• News Briefs 

• Allen Brain Atlas Updated
  Powerful new tools expand offerings.
• Keep DREAM('n)
  Competition tests models of biological systems. 

Computational Development

• Driving DNA Interference (DNAi)
  DNAi may one day rival RNAi in the quest for safe, effective nucleic acid drug delivery.

 IT/Workflow

• Looking into Drug Discovery Data
  Growing dimensions make data harder to visualize; software adds interactive twists.
• Symyx Acquires MDL Information Systems
  Transaction brings tools and databases to Symyx.

Clinical Research

• ProSanos Launches Pharmacovigilance Tool
  CLÆRITY helps make sense of FDA adverse event database.
• Art Exhibit Highlights Drug Safety
  Quintiles Transnational Corp. sponsors image exhibit highlighting safety in clinical trials.
• Square Pegs in Round Holes?
  Early data standardization poses problems.
• Relsys Enabling "Structured" Signal Management
  Toolkit addresses elements of drug safety surveillance.

In Every Issue

• Predicting Dose Response
  FIRST BASE - Drug labels and gene therapy examples illustrate drug dosage dilemmas.
  By Kevin Davies
• BGM Plans IPO; Welcome to MIAPE and MIMIx
  THE RUSSELL TRANSCRIPT - Who says August is slow? IPOs and standards are making news.
  By John Russell
• New Products